Fatty acid–free human serum albumin and tetramethylrhodamine (TRITC) phalloidin were provided by Sigma‐Aldrich (St. Louis, MO, USA). Fibrinogen was from Fresenius Kabi (Lake Zurich, IL, USA). Horm fibrillar type‐I collagen from equine Achilles tendon, used to coat flow chambers (200 μg/ml) was purchased from Takeda (Tokyo, Japan).
ReoPro was from Eli Lilly (Indianapolis, IN, USA). The anti‐GPVI blocking antibody, 1G5, was developed by Elizabeth Gardiner (ANU, Australia). IV.3 was from Stemcell Technologies (Vancouver, BC, Canada). The mouse IgG2b use as a negative control (clone MPC‐11) was from Merck‐Millipore (Molsheim, France). RAM‐1 is an anti‐GPIbβ antibody developed at U1255 (François Lanza).
Recombinant hirudin, used as an anticoagulant to directly block thrombin (100 U/mL), was from Transgene (Illkirch‐Graffenstaden, France). 3,3’‐dihexyloxacarbocyanine iodide (DIOC
6) was from Molecular Probes (Paisley, UK).
Paraformaldehyde was from VWR (Strasbourg, France).
Ahmed M.U., Receveur N., Janus‐Bell E., Mouriaux C., Gachet C., Jandrot‐Perrus M., Hechler B., Gardiner E.E, & Mangin P.H. (2021). Respective roles of Glycoprotein VI and FcγRIIA in the regulation of αIIbβ3‐mediated platelet activation to fibrinogen, thrombus buildup, and stability. Research and Practice in Thrombosis and Haemostasis, 5(5), e12551.